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Antivirals represent a rational approach to the management of influenza, but prior to 
approval of the neuraminidase inhibitors (NIs), zanamivir and oseltamivir, in 1999, only the 
M2-inhibitors, amantadine and rimantadine, were available, with limitations of rapid 
emergence of resistance, lack of activity against influenza B, and adverse central nervous 
system events. Oseltamivir is effectively the only antiviral widely available to manage 
influenza because administration of zanamivir by inhalation restricts its utility. NIs are used 
widely in Japan to treat seasonal influenza, but more cautiously elsewhere, driven by 
uncertainties about clinical benefit.  
 
In 2005, a large international hearing co-hosted by WHO, FAO, OIE, and the World Bank 
noted the severity of avian A(H5N1) influenza (53.4% case fatality during 2003-05) and its 
considerable pandemic potential. Remarking on limited clinical data on NIs for treatment of 
human infection with H5N1, resistance of circulating strains to M2-inhibitors, challenges 
over vaccine procurement, and limited production capacity for NIs, members of the hearing 
recommended expansion of the global antiviral stockpile.1 Contrary to expectation, the 
following pandemic in 2009 was caused by an A(H1N1) virus and killed ~284 500 people,2 
many fewer than pandemics of 1918, 1957, and 1968, prompting questions about the 
rationale of stockpiling neuraminidase inhibitors. So, does the updated Cochrane Review3 
provide incontrovertible evidence to justify or dismiss NIs for treating influenza?   
 
The short answer is no. Altogether 107 reports were available but only 46 (20 oseltamivir, 26 
zanamivir) were subjected to meta-analysis. The authors concluded that oseltamivir reduced 
time to alleviation of symptoms of influenza-like illness modestly, in adults and children by 
16.8 and 29 hours respectively – confirming efficacy against trial endpoints. Oseltamivir had 
no significant effects on pneumonia, serious complications, hospitalisations or deaths, 
leading the authors to conclude, “treatment trials do not settle the question whether the 
complications of influenza (such as pneumonia) are reduced, because of a lack of 
definitions”.3  However, they acknowledge that included trials were mainly conducted in 
community settings against “relatively benign influenza”2 [seasonal influenza] and there 
were “problems in the design of many of the studies that were included”.3  Simply put, the 
individual trials were not designed or powered to assess impact on severe illness or 
hospitalisations (Table 1), or deaths; the latter did not occur in any oseltamivir study.  
 
 
 
 
 
 
 
 
 
Table 1: Examples of subject numbers included for analyses pertaining to oseltamivir3 
 
Patient group Outcome Number* 
Adults Hospital admission 4394 
Children Hospital admission 1359 
All ages Pneumonia 4452 
Serious complications 3675 
*total of subjects with influenza-like illness assigned to active treatment or placebo: Influenza confirmed in ~64% of adults and 
~53% of children. 
 
Data on adverse events are more extensive and reassuring than in the last Cochrane review.  
Altogether, gastrointestinal events occurred in 24.0% of adults and 23.1% of children during 
the on-treatment period for influenza-like illness as compared with 17.8% (RR 1.25, 95%CI 
1.08-1.45) and 19.5% (RR 1.18, 95%CI 0.96-1.44) respectively with placebo. Withdrawals due 
to adverse events and occurrence of psychiatric manifestations were similar with oseltamivir 
or placebo.3 Intriguingly, oseltamivir significantly decreased the risk of undefined cardiac 
events compared to placebo during the on-treatment period (risk difference 0.68%, 95% CI 
0.04 to 1.0), suggesting a plausible benefit of treatment.3  
 
Clearly, efficacy data from the latest Cochrane Review cannot be applied confidently to 
formulate treatment policy or guidance for the management of patients hospitalised with 
seasonal influenza, especially those with life-threatening disease. The same applies to 
pandemic planning and stockpiling of antivirals.  In these settings, which contrast to those in 
the Cochrane Review, policy-makers can draw on evidence from observational studies, 
accepting that they are more prone to bias. Nevertheless a substantial body of evidence 
suggests that NIs reduce complications and mortality in patients with severe influenza.4-6 
The evidence is especially strong from the 2009 pandemic period where a very large 
individual participant data (IPD) analysis based on 29 234 hospitalised subjects, of whom 
86% had laboratory confirmed A(H1N1)pdm09, has recently demonstrated that mortality 
was reduced by one fifth overall, and by one half if treatment was started within 48 hours of 
illness onset.7 
 
Taken together, the latest Cochrane Review findings (on treatment and prophylaxis) and 
those of recent observational studies (on complications and mortality) are not in conflict, 
but point to oseltamivir being an essential part of our defence against influenza. 
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